Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
MaxCyte Inc on Wednesday said it has signed a strategic platform licence with TG Therapeutics Inc to develop its autoimmune cell therapy.
The Rockville, Maryland-based provider of cell engineering platform technologies said it will receive annual licensing fees and program-related revenue under the agreement.
TG Therapeutics gains research, clinical and commercial rights to use MaxCyte’s flow electroporation technology and Expert platform to support the development of azer-cel, a cell therapy programme to treat autoimmune diseases.
Chief Executive Officer Maher Masoud said: ‘By leveraging our commercially validated cell-engineering platform and optimized T cell manufacturing workflow, TG Therapeutics is advancing toward their phase 1 clinical trial for the application of azer-cel in progressive forms of MS... With our new partnership, we will continue to support the development of azer-cel to expand the application to autoimmune diseases.’
Shares in MaxCyte were up 0.7% to 342.50 pence in London on Wednesday morning.
Copyright 2025 Alliance News Ltd. All Rights Reserved.